FDA Approves Ziihera in First-Line HER2+ GEA, Triggering $250M Milestone for Zymeworks
ZYME has more than doubled off its 52-week low of $13.6 on light trading volume (0.4× avg).
Summary
The FDA approved Ziihera (zanidatamab) for first-line HER2-positive gastroesophageal adenocarcinoma, both with and without tislelizumab plus chemotherapy. This is the second approval for the drug, which Zymeworks discovered and licensed to Jazz Pharmaceuticals. The approval triggers a $250 million milestone payment to Zymeworks, bringing total Jazz payments to $650 million, with up to $1.3 billion in additional milestones and 10-20% royalties on Jazz sales. The approval was expected—the PDUFA date was today—but confirmation removes a key binary risk and validates the Azymetric platform. Zymeworks also has a separate collaboration with BeOne Medicines for zanidatamab in other territories, with up to $144 million in remaining milestones and up to 19.5% royalties. The company's cash position was $322.5 million as of Q2, so this milestone is highly material. The stock is trading near its 52-week high, suggesting the market had priced in a high probability of approval, but the formal announcement and milestone confirmation are still significant. Next catalysts include additional regulatory submissions by Jazz and BeOne, and the ongoing HERIZON-GEA-301 confirmatory trial.
At the time of this announcement, ZYME was trading at $29.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $13.60 to $29.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.